Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.
Objective: To define variation in L-dopa response in recent onset PD. Background: L-Dopa responsiveness is a defining feature of Parkinson’s disease (PD), but the degree…Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…Preliminary results of a cross-linguistic comparison on dysarthria in Parkinson’s disease
Objective: To evaluate the effects of language, disease duration, and medication on acoustic and prosodic parameters in the speech of Parkinson's disease (PD) patients. Background:…MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum
Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…Experience with utilization of rytary in the clinical setting
Objective: To explore the utilization and tolerability of Rytary in the clinical setting. Background: Rytary is a novel extended-release carbidopa-levodopa (CD-LD) formulation that was approved…The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients
Objective: To assess the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on activities of daily…Comorbid conditions associated with Parkinson´s disease: A longitudinal study
Objective: (1)To study what comorbid conditions were present at baseline and 3 years later in a cohort of Spanish PD patients and (2) to analyze…Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets
Objective: To determine the role of M4 muscarinic receptors in the expression of L-DOPA-induced dyskinesia (LID) and dystonia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Background:…Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients
Objective: To determine whether levodopa-carbidopa intestinal gel (LCIG) infusion is able to improve freezing of gait (FOG) in advanced Parkinson's disease (PD) patients. Background: FOG…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 57
- Next Page »